Global pharmaceutical giants AstraZeneca and Bristol Myers Squibb are reportedly in preliminary discussions over a potential merger valued at approximately $400 billion, a deal that could become the largest pharmaceutical merger in history if successfully completed. The reported negotiations have attracted significant attention from investors, healthcare analysts, and regulatory authorities worldwide due to the scale of the proposed transaction and its potential impact on the